Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00210340
Status:
WITHDRAWN
Last Update Posted:
2015-03-30
First Post:
2005-09-13
Brief Title:
A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
Sponsor:
International Extranodal Lymphoma Study Group IELSG
Organization:
International Extranodal Lymphoma Study Group IELSG
Study Overview
Official Title:
A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
Status:
WITHDRAWN
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
lack of accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to define the safety profile of rituximab given intrathecally in lymphomatous meningitis related to CD20 non-Hodgkins lymphomas
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None